Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing.

BACKGROUND: Chronic kidney disease (CKD) results in a dramatic increase in skeletal fracture risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but they are not recommended in advanced CKD. We have recently shown higher acute skeletal accumulation of fluorescently-tagged...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Bone
Autors principals: Swallow, Elizabeth A., Aref, Mohammad W., Metzger, Corinne E., Sacks, Spencer, Lehmkuhler, Demi R., Chen, Neal, Hammond, Max A., Territo, Paul R., Nickolas, Thomas L., Moe, Sharon M., Allen, Matthew R.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6708715/
https://ncbi.nlm.nih.gov/pubmed/31299384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2019.07.007
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars